Importer of Controlled Substances, Notice of Application; Meridian Medical Technologies, 15974-15975 [2013-05793]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
15974
Federal Register / Vol. 78, No. 49 / Wednesday, March 13, 2013 / Notices
Bishop’s Lodge Road, Tesuque, New
Mexico, 87574.
• Pojoaque—Pojoaque Valley School
District Campus, West Wing Conference
Room, 1574 State Road 502 West, Santa
Fe, New Mexico 87506.
• Santa Fe—Santa Fe Community
College, Jemez Rooms 1&2, 6401
Richards Avenue, Santa Fe, New
Mexico 87508.
˜
• Espanola—Northern New Mexico
College, Cafeteria, 921 N. Paseo de
˜
˜
Onate, Espanola, New Mexico 87532.
• Taos—Taos Convention Center, Rio
Grande Hall, Room A, 120 Civic Plaza,
Taos, New Mexico 87571.
FOR FURTHER INFORMATION CONTACT: Ms.
Molly Thrash, Bureau of Reclamation,
Albuquerque Area Office, 555 Broadway
NE., Suite 100, Albuquerque, New
Mexico, 87102; telephone (505) 462–
3702; facsimile (505) 462–3780; email
sthrash@usbr.gov. Persons who use a
telecommunications device for the deaf
may call the Federal Information Relay
Service (FIRS) at 1–800–877–8339 to
contact the above individual during
normal business hours. The FIRS is
available 24 hours a day, 7 days a week
to leave a message or question with the
above individual. You will receive a
reply during normal business hours.
SUPPLEMENTARY INFORMATION: The
Bureau of Reclamation is the lead
Federal agency for preparation of the
Pojoaque Basin Regional Water System
Environmental Impact Statement (EIS).
As such, Reclamation published a
Notice of Intent to Prepare an EIS on
February 24, 2012 (77 FR 11155). The
U.S. Army Corps of Engineers, Bureau
of Indian Affairs, U.S. Fish and Wildlife
Service, Indian Health Service, New
Mexico Department of Transportation,
New Mexico Office of the State
Engineer, County of Santa Fe, City of
´
Santa Fe, and the Pueblos of Nambe,
Pojoaque, San Ildefonso, and Tesuque
have been invited to participate as
cooperating agencies. Other entities may
be considered as necessary during the
EIS process.
Reclamation is proposing to plan,
design, and construct the Pojoaque
Basin Regional Water System in
accordance with the Aamodt Litigation
Settlement Act, which is Title VI of the
Claims Resolution Act of 2010 (Pub. L.
111–291, Title VI; 124 Stat. 3065). The
proposed project would divert, treat,
and distribute potable water to the
Pueblo and non-Pueblo residents of the
Pojoaque Basin. The Regional Water
System would consist of surface water
diversion and water treatment facilities
within the boundaries of San Ildefonso
Pueblo on the Rio Grande and storage
tanks, transmission and distribution
VerDate Mar<15>2010
17:11 Mar 12, 2013
Jkt 229001
pipelines, and aquifer storage and
recovery well fields that would supply
up to 4,000 acre-feet of water annually
to customers within the Pojoaque Basin.
Additional Information on the project
is available at the project Web site at
PojoaqueBasinEIS.com.
Public Scoping
Scoping is an early, ongoing, and
open public process for determining the
relevant issues to be addressed in the
EIS and for identifying any significant
issues and suggested alternatives related
to the proposed Federal action.
Public comments on the scope and
content of the EIS may be provided at
the public meetings, submitted online
through the project Web site, sent via
email or facsimile, or mailed to the
address shown below. To be most
effectively considered, comments
should be submitted by May 3, 2013.
Public comments and/or requests to
be added to the project mailing list will
be accepted at all of the public scoping
meetings or by any of the methods
shown below:
• Email: PojoaqueBasinEIS@usbr.gov.
• Facsimile: (505) 462–3780.
• Web site: PojoaqueBasinEIS.com.
• Address: Bureau of Reclamation,
Albuquerque Area Office, Suite 100
(ALB–842), 555 Broadway NE., Suite
100, Albuquerque, New Mexico, 87102.
In addition to the public scoping
meetings described above, Reclamation
may host additional scoping meetings
with Pueblo members at or near each of
the four Pueblos. Government-togovernment consultation will continue
with the Pueblo governments and
coordination will continue with other
Federal and State agencies.
Special Assistance for Public Meetings
If special assistance is required to
participate in a particular scoping
meeting, please contact Ms. Molly
Thrash at (505) 462–3702, or via email
at sthrash@usbr.gov. A telephone device
for the hearing impaired is available at
1–800–877–8339. Please provide
notification as far in advance as possible
to enable Reclamation to secure the
needed services. If a request cannot be
honored, the requestor will be notified.
Public Disclosure
Before including your address, phone
number, email address, or other
personal identifying information in any
communication, you should be aware
that your entire comments—including
your personal identifying information—
may be made publicly available at any
time. While you can ask us in your
communication to withhold your
personal identifying information from
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
public review, we cannot guarantee that
we will be able to do so.
Dated: January 16, 2013.
Larry Walkoviak,
Regional Director—Upper Colorado Region,
Bureau of Reclamation.
[FR Doc. 2013–05604 Filed 3–12–13; 8:45 am]
BILLING CODE 4310–MN–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances,
Notice of Application; Meridian Medical
Technologies
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on January 8, 2013, Meridian
Medical Technologies, 2555 Hermelin
Drive, St. Louis, Missouri 63144, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Morphine (9300), a basic class of
controlled substance listed in schedule
II.
The company manufactures a product
containing morphine in the United
States. The company exports this
product to customers around the world.
The company has been asked to ensure
that its product sold to European
customers meets standards established
by the European Pharmacopeia, which
is administered by the Directorate for
the Quality of Medicines (EDQM). In
order to ensure that its product will
meet European specifications, the
company seeks to import morphine
supplied by EDQM to use as reference
standards. This is the sole purpose for
which the company will be authorized
by DEA to import morphine.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
listed in schedule II, which falls under
the authority of section 1002(a)(2)(B) of
the Act (21 U.S.C. 952(a)(2)(B)) may, in
the circumstances set forth in 21 U.S.C.
958(i), file comments or objections to
the issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 12, 2013.
E:\FR\FM\13MRN1.SGM
13MRN1
Federal Register / Vol. 78, No. 49 / Wednesday, March 13, 2013 / Notices
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substances in schedules
I or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: March 7, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on DSK4VPTVN1PROD with NOTICES
Importer of Controlled Substances,
Notice of Registration: Hospira Inc.
By Notice dated December 14, 2012,
and published in the Federal Register
on December 21, 2012, 77 FR 75670,
Hospira Inc., 1776 North Centennial
Drive, McPherson, Kansas 67460–1247,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Remifentanil (9739), a basic class of
controlled substance listed in schedule
II.
The company plans to import
Remifentanil for use in dosage form
manufacturing.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Hospira Inc. to import the basic class of
controlled substance is consistent with
the public interest, and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971, at this time. DEA
has investigated Hospira Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
17:11 Mar 12, 2013
Jkt 229001
Dated: March 7, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–05794 Filed 3–12–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Registration;
Johnson Matthey, Inc.,
Pharmaceuticals Materials
By Notice dated November 1, 2012,
and published in the Federal Register
on November 9, 2012, 77 FR 67397,
Johnson Matthey, Inc., Pharmaceuticals
Materials, 900 River Road,
Conshohocken, Pennsylvania 19428,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
[FR Doc. 2013–05793 Filed 3–12–13; 8:45 am]
VerDate Mar<15>2010
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Codeine (9050) .............................
Oxycodone (9143) ........................
Diphenoxylate (9170) ...................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Thebaine (9333) ...........................
I
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its
customers.
The Thebaine (9333) will also be used
to manufacture other controlled
substances for sale in bulk to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc., Pharmaceuticals
Materials to manufacture the listed basic
classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Johnson
Matthey Inc., Pharmaceuticals Materials
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
PO 00000
Frm 00048
Fmt 4703
Sfmt 9990
15975
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: February 27, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–05799 Filed 3–12–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Office of the Secretary
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Job Clubs
Study
ACTION:
Notice; correction.
The Department of Labor
published a document in the Federal
Register of February 26, 2013,
concerning request for comments on site
visits to job clubs. The document
contained incorrect dates.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Contact Ben Seigel by telephone at 202–
693–6032 (this is not a toll-free number)
or by email at CFBNP@dol.gov.
Correction
In the Federal Register of February
26, 2013, in FR Doc. 2013–04391, on
page 13086, in the second column,
correct the DATES caption to read:
Written comments must be
submitted to the office listed in the
addressee section on or before April 27,
2013.
DATES:
Signed at Washington, DC, this 5th day of
March, 2013.
Irasema Garza,
Acting Assistant Secretary for Policy, U.S.
Department of Labor .
[FR Doc. 2013–05775 Filed 3–12–13; 8:45 am]
BILLING CODE P
E:\FR\FM\13MRN1.SGM
13MRN1
]]>Agencies
[Federal Register Volume 78, Number 49 (Wednesday, March 13, 2013)]
[Notices]
[Pages 15974-15975]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-05793]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances, Notice of Application;
Meridian Medical Technologies
Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this
is notice that on January 8, 2013, Meridian Medical Technologies, 2555
Hermelin Drive, St. Louis, Missouri 63144, made application by renewal
to the Drug Enforcement Administration (DEA) to be registered as an
importer of Morphine (9300), a basic class of controlled substance
listed in schedule II.
The company manufactures a product containing morphine in the
United States. The company exports this product to customers around the
world. The company has been asked to ensure that its product sold to
European customers meets standards established by the European
Pharmacopeia, which is administered by the Directorate for the Quality
of Medicines (EDQM). In order to ensure that its product will meet
European specifications, the company seeks to import morphine supplied
by EDQM to use as reference standards. This is the sole purpose for
which the company will be authorized by DEA to import morphine.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance listed in schedule II, which falls under the authority of
section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the
circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR
1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than April 12, 2013.
[[Page 15975]]
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substances
in schedules I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: March 7, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-05793 Filed 3-12-13; 8:45 am]
BILLING CODE 4410-09-P
